Storm Therapeutics entered a strategic collaboration with Alida Biosciences to quantify transcript‑specific N6‑methyladenosine (m6A) RNA modifications in clinical samples from patients treated with Storm’s METTL3 inhibitor STC‑15. The partnership will apply AlidaBio’s EpiPlex and EpiScout sequencing platforms to validate m6A dynamics, identify biomarker signatures, and guide patient selection strategies in ongoing Phase 1b/2 studies. Storm noted STC‑15 is the first small‑molecule METTL3 inhibitor in human trials and is being evaluated in combination with PD‑1 blockade across several solid tumors. The collaboration aims to correlate m6A modulation with clinical outcomes and accelerate translational endpoints for epitranscriptomic therapies. Clarification: METTL3 is an RNA methyltransferase that installs m6A, an epitranscriptomic mark implicated in RNA stability and translation.